Vejledning til udredning og behandling af osteoporose - Dansk ...

26 DANSK KNOGLEMEDICINSK SELSKAB
Litteratur
1. Pedersen T, Gluud CN, Gotzsche PC, Matzen P, Wille-Jorgensen PA. Hvad er
evidensbaseret medicin? Ugeskr Laeger 2001; 163:3769-3772.
2. Anon. Consensus development conference: diagnosis, prophylaxis and treatment
of osteoporosis. Am J Med 1993; 94:646-650.
3. McLellan AR, Gallacher SJ, Fraser M, McQuillian C. The fracture liaison service:
success of a program for the evaluation and management of patients with
osteoporotic fracture. Osteoporos Int 2003; 14:1028-1034.
4. Kanis JA, Melton LJ, III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis
of osteoporosis. J Bone Miner Res 1994; 9:1137-1141.
5. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral
density. J Bone Miner Res 1993; 8:1-9.
6. Makovey J, Nguyen TV, Naganathan V, Wark JD, Sambrook PN. Genetic Effects
on Bone Loss in Peri- and Postmenopausal Women: A Longitudinal Twin
Study. Journal of Bone and Mineral Research 2007; 22:1773-1780.
7. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic
determinants of bone mass in adults. A twin study. J Clin Invest 1987; 80:706-710.
8. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P et al. Predictive
value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185-
1194.
9. Leslie WD, Tsang JF, Caetano PA, Lix LM, for the Manitoba Bone Density Program.
Effectiveness of Bone Density Measurement for Predicting Osteoporotic
Fractures in Clinical Practice. Journal of Clinical Endocrinology Metabolism
2007; 92:77-81.
10. Canalis E, Giustina A, Bilezikian JP. Mechanisms of Anabolic Therapies for
Osteoporosis. N Engl J Med 2007; 357:905-916.
11. Riggs BL, Khosla S, Melton LJ, III. Sex Steroids and the Construction and Conservation
of the Adult Skeleton. Endocr Rev 2002; 23:279-302.
12. Vestergaard P. Fracture risk secondary to disease [Thesis]. Aarhus: Fællestrykkeriet
for Sundhedsvidenskab; 2003.
13. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am
2003; 32:115-34, vii.
14. Nielsen LR, Vestergaard P, Mosekilde L. [Drugs with side effects affecting calcium
homeostasis, bone metabolism and risk of fractures]. Ugeskr Laeger 2005;
167:1026-1030.
15. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed:
a nationwide study from Denmark. Osteoporos Int 2005; 16:134-141.
16. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis
and osteoporotic fractures. Epidemiol Rev 1985; 7:178-208.
17. Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC et al.
Long-term prediction of incident hip fracture risk in elderly white women:
study of osteoporotic fractures. J Am Geriatr Soc 2004; 52:1479-1486.
18. van der KM, de Laet CE, McCloskey EV, Johnell O, Kanis JA, Hofman A et al.
Risk factors for incident vertebral fractures in men and women: the Rotterdam
Study. J Bone Miner Res 2004; 19:1172-1180.
19. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA et al. Smoking
and fracture risk: a meta-analysis. Osteoporos Int 2005; 16:155-162.
20. Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a meta-analysis.
J Intern Med 2003; 254:572-583.
21. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al. A metaanalysis
of previous fracture and subsequent fracture risk. Bone 2004; 35:375-
382.
22. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA et al. Alcohol
intake as a risk factor for fracture. Osteoporos Int 2005; 16:737-742.
23. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of
bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;
312:1254-1259.
24. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis
and treatment of osteoporosis. Postgrad Med J 2007; 83:509-517.
25. Abrahamsen B, Nissen N, Hermann AP, Hansen B, Barenholdt O, Vestergaard
P et al. When should densitometry be repeated in healthy peri- and postmenopausal
women: the Danish osteoporosis prevention study. J Bone Miner Res
2002; 17:2061-2067.
26. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs J, Lentle BC. Precision
Assessment and Radiation Safety for Dual-Energy X-Ray Absorptiometry:
Position Paper of the International Society for Clinical Densitometry. Journal of
Clinical Densitometry 2005; 8:371-378.
27. Vokes T, Bachman D, Baim S, Binkley N, Broy S, Ferrar L et al. Vertebral Fracture
Assessment: The 2005 ISCD Official Positions. Journal of Clinical Densitometry
2006; 9:37-46.
28. Peh WC, Khong PL, Yin Y, Ho WY, Evans NS, Gilula LA et al. Imaging of pelvic
insufficiency fractures. Radiographics 1996; 16:335-348.
29. Weber M, Hasler P, Gerber H. Insufficiency fractures of the sacrum. Twenty
cases and review of the literature. Spine 1993; 18:2507-2512.
30. Mosekilde L, Nielsen LR, Larsen ER, Moosgaard B, Heickendorff L. [Vitamin D
deficiency. Definition and prevalence in Denmark]. Ugeskr Laeger 2005; 167:29-
33.
31. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or
calcium in combination with vitamin D supplementation to prevent fractures
and bone loss in people aged 50 years and older: a meta-analysis. The Lancet
370:657-666.
32. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D
and calcium supplementation reduces cancer risk: results of a randomized trial.
American Journal of Clinical Nutrition 2007; 85:1586-1591.
33. Autier P, Gandini S. Vitamin D Supplementation and Total Mortality: A Metaanalysis
of Randomized Controlled Trials. Arch Intern Med 2007; 167:1730-1737.
34. Holick MF. Vitamin D Deficiency. N Engl J Med 2007; 357:266-281.
35. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al. Calcium
plus vitamin D supplementation and the risk of fractures. N Engl J Med
2006; 354:669-683.
36. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH.
Interventions for preventing falls in elderly people. Cochrane Database Syst
Rev 2003;CD000340.
37. Close JC, Hooper R, Glucksman E, Jackson SH, SWIFT CG. Predictors of falls
in a high risk population: results from the prevention of falls in the elderly trial
(PROFET). Emerg Med J 2003; 20:421-425.
38. Sundhedsstyrelsen. Faldpatienter i den kliniske hverdag – rådgivning fra Sundhedsstyrelsen.
København: Sundhedsstyrelsen; 2006.
39. Mazess RB, Whedon GD. Immobilization and bone. Calcif Tissue Int 1983;
35:265-267.
40. Tinetti ME. Performance-oriented assessment of mobility problems in elderly
patients. J Am Geriatr Soc 1986; 34:119-126.
41. Schwarz P. Physical activity and bone strength. Scand J Med Sci Sports 2004;
14:1.
42. Palombaro KM. Effects of walking-only interventions on bone mineral density
at various skeletal sites: a meta-analysis. J Geriatr Phys Ther 2005; 28:102-107.
43. Martyn-St James M, Carroll S. High-intensity resistance training and postmenopausal
bone loss: a meta-analysis. Osteoporosis International 2006; 17:1225-
1240.
44. Hoidrup S, Sorensen TI, Stroger U, Lauritzen JB, Schroll M, Gronbaek M.
Leisure-time physical activity levels and changes in relation to risk of hip fracture
in men and women. Am J Epidemiol 2001; 154:60-68.
45. Feskanich D, Willett W, Colditz G. Walking and Leisure-Time Activity and Risk
of Hip Fracture in Postmenopausal Women. JAMA: The Journal of the American
Medical Association 2002; 288:2300-2306.
46. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip
fractures. Lancet 1993; 341:11-13.
47. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures
in the elderly. Cochrane Database Syst Rev 2003;CD001255.
48. Ilich JZ, Brownbill RA, Tamborini L, Crncevic-Orlic Z. To Drink or Not to
Drink: How Are Alcohol, Caffeine and Past Smoking Related to Bone Mineral
Density in Elderly Women? J Am Coll Nutr 2002; 21:536-544.
49. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V et al. II.
Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women.
Endocr Rev 2002; 23:508-516.
50. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A et al. III.
Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis.
Endocr Rev 2002; 23:517-523.
51. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C
et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture.
N Engl J Med 2007;NEJMoa074941.
52. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al.
Treatment With Once-Weekly Alendronate 70 mg Compared With Once-
Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis:
A Randomized Double-Blind Study. Journal of Bone and Mineral Research
2005; 20:141-151.
53. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al.
Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force
of the American Society for Bone and Mineral Research. Journal of Bone and
Mineral Research 2000; 0:1-45.
54. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant
HK et al. Reduction of vertebral fracture risk in postmenopausal women with
osteoporosis treated with raloxifene: results from a 3-year randomized clinical
trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA
1999; 282:637-645.
55. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J et al. IV.
Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal
Osteoporosis. Endocr Rev 2002; 23:524-528.
56. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A et al.